Cargando…
Genome-wide CRISPR/Cas9 knockout screening uncovers a novel inflammatory pathway critical for resistance to arginine-deprivation therapy
Arginine synthesis deficiency due to the suppressed expression of ASS1 (argininosuccinate synthetase 1) represents one of the most frequently occurring metabolic defects of tumor cells. Arginine-deprivation therapy has gained increasing attention in recent years. One challenge of ADI-PEG20 (pegylate...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7914361/ https://www.ncbi.nlm.nih.gov/pubmed/33664852 http://dx.doi.org/10.7150/thno.51795 |
_version_ | 1783656984812191744 |
---|---|
author | Chu, Cheng-Ying Lee, Yi-Ching Hsieh, Cheng-Han Yeh, Chi-Tai Chao, Tsu-Yi Chen, Po-Hung Lin, I-Hsuan Hsieh, Tsung-Han Shih, Jing-Wen Cheng, Chia-Hsiung Chang, Che-Chang Lin, Ping-Sheng Huang, Yuan-Li Chen, Tsung-Ming Yen, Yun Ann, David K. Kung, Hsing-Jien |
author_facet | Chu, Cheng-Ying Lee, Yi-Ching Hsieh, Cheng-Han Yeh, Chi-Tai Chao, Tsu-Yi Chen, Po-Hung Lin, I-Hsuan Hsieh, Tsung-Han Shih, Jing-Wen Cheng, Chia-Hsiung Chang, Che-Chang Lin, Ping-Sheng Huang, Yuan-Li Chen, Tsung-Ming Yen, Yun Ann, David K. Kung, Hsing-Jien |
author_sort | Chu, Cheng-Ying |
collection | PubMed |
description | Arginine synthesis deficiency due to the suppressed expression of ASS1 (argininosuccinate synthetase 1) represents one of the most frequently occurring metabolic defects of tumor cells. Arginine-deprivation therapy has gained increasing attention in recent years. One challenge of ADI-PEG20 (pegylated ADI) therapy is the development of drug resistance caused by restoration of ASS1 expression and other factors. The goal of this work is to identify novel factors conferring therapy resistance. Methods: Multiple, independently derived ADI-resistant clones including derivatives of breast (MDA-MB-231 and BT-549) and prostate (PC3, CWR22Rv1, and DU145) cancer cells were developed. RNA-seq and RT-PCR were used to identify genes upregulated in the resistant clones. Unbiased genome-wide CRISPR/Cas9 knockout screening was used to identify genes whose absence confers sensitivity to these cells. shRNA and CRISPR/Cas9 knockout as well as overexpression approaches were used to validate the functions of the resistant genes both in vitro and in xenograft models. The signal pathways were verified by western blotting and cytokine release. Results: Based on unbiased CRISPR/Cas9 knockout screening and RNA-seq analyses of independently derived ADI-resistant (ADIR) clones, aberrant activation of the TREM1/CCL2 axis in addition to ASS1 expression was consistently identified as the resistant factors. Unlike ADIR, MDA-MB-231 overexpressing ASS1 cells achieved only moderate ADI resistance both in vitro and in vivo, and overexpression of ASS1 alone does not activate the TREM1/CCL2 axis. These data suggested that upregulation of TREM1 is an independent factor in the development of strong resistance, which is accompanied by activation of the AKT/mTOR/STAT3/CCL2 pathway and contributes to cell survival and overcoming the tumor suppressive effects of ASS1 overexpression. Importantly, knockdown of TREM1 or CCL2 significantly sensitized ADIR toward ADI. Similar results were obtained in BT-549 breast cancer cell line as well as castration-resistant prostate cancer cells. The present study sheds light on the detailed mechanisms of resistance to arginine-deprivation therapy and uncovers novel targets to overcome resistance. Conclusion: We uncovered TREM1/CCL2 activation, in addition to restored ASS1 expression, as a key pathway involved in full ADI-resistance in breast and prostate cancer models. |
format | Online Article Text |
id | pubmed-7914361 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Ivyspring International Publisher |
record_format | MEDLINE/PubMed |
spelling | pubmed-79143612021-03-03 Genome-wide CRISPR/Cas9 knockout screening uncovers a novel inflammatory pathway critical for resistance to arginine-deprivation therapy Chu, Cheng-Ying Lee, Yi-Ching Hsieh, Cheng-Han Yeh, Chi-Tai Chao, Tsu-Yi Chen, Po-Hung Lin, I-Hsuan Hsieh, Tsung-Han Shih, Jing-Wen Cheng, Chia-Hsiung Chang, Che-Chang Lin, Ping-Sheng Huang, Yuan-Li Chen, Tsung-Ming Yen, Yun Ann, David K. Kung, Hsing-Jien Theranostics Research Paper Arginine synthesis deficiency due to the suppressed expression of ASS1 (argininosuccinate synthetase 1) represents one of the most frequently occurring metabolic defects of tumor cells. Arginine-deprivation therapy has gained increasing attention in recent years. One challenge of ADI-PEG20 (pegylated ADI) therapy is the development of drug resistance caused by restoration of ASS1 expression and other factors. The goal of this work is to identify novel factors conferring therapy resistance. Methods: Multiple, independently derived ADI-resistant clones including derivatives of breast (MDA-MB-231 and BT-549) and prostate (PC3, CWR22Rv1, and DU145) cancer cells were developed. RNA-seq and RT-PCR were used to identify genes upregulated in the resistant clones. Unbiased genome-wide CRISPR/Cas9 knockout screening was used to identify genes whose absence confers sensitivity to these cells. shRNA and CRISPR/Cas9 knockout as well as overexpression approaches were used to validate the functions of the resistant genes both in vitro and in xenograft models. The signal pathways were verified by western blotting and cytokine release. Results: Based on unbiased CRISPR/Cas9 knockout screening and RNA-seq analyses of independently derived ADI-resistant (ADIR) clones, aberrant activation of the TREM1/CCL2 axis in addition to ASS1 expression was consistently identified as the resistant factors. Unlike ADIR, MDA-MB-231 overexpressing ASS1 cells achieved only moderate ADI resistance both in vitro and in vivo, and overexpression of ASS1 alone does not activate the TREM1/CCL2 axis. These data suggested that upregulation of TREM1 is an independent factor in the development of strong resistance, which is accompanied by activation of the AKT/mTOR/STAT3/CCL2 pathway and contributes to cell survival and overcoming the tumor suppressive effects of ASS1 overexpression. Importantly, knockdown of TREM1 or CCL2 significantly sensitized ADIR toward ADI. Similar results were obtained in BT-549 breast cancer cell line as well as castration-resistant prostate cancer cells. The present study sheds light on the detailed mechanisms of resistance to arginine-deprivation therapy and uncovers novel targets to overcome resistance. Conclusion: We uncovered TREM1/CCL2 activation, in addition to restored ASS1 expression, as a key pathway involved in full ADI-resistance in breast and prostate cancer models. Ivyspring International Publisher 2021-01-25 /pmc/articles/PMC7914361/ /pubmed/33664852 http://dx.doi.org/10.7150/thno.51795 Text en © The author(s) This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions. |
spellingShingle | Research Paper Chu, Cheng-Ying Lee, Yi-Ching Hsieh, Cheng-Han Yeh, Chi-Tai Chao, Tsu-Yi Chen, Po-Hung Lin, I-Hsuan Hsieh, Tsung-Han Shih, Jing-Wen Cheng, Chia-Hsiung Chang, Che-Chang Lin, Ping-Sheng Huang, Yuan-Li Chen, Tsung-Ming Yen, Yun Ann, David K. Kung, Hsing-Jien Genome-wide CRISPR/Cas9 knockout screening uncovers a novel inflammatory pathway critical for resistance to arginine-deprivation therapy |
title | Genome-wide CRISPR/Cas9 knockout screening uncovers a novel inflammatory pathway critical for resistance to arginine-deprivation therapy |
title_full | Genome-wide CRISPR/Cas9 knockout screening uncovers a novel inflammatory pathway critical for resistance to arginine-deprivation therapy |
title_fullStr | Genome-wide CRISPR/Cas9 knockout screening uncovers a novel inflammatory pathway critical for resistance to arginine-deprivation therapy |
title_full_unstemmed | Genome-wide CRISPR/Cas9 knockout screening uncovers a novel inflammatory pathway critical for resistance to arginine-deprivation therapy |
title_short | Genome-wide CRISPR/Cas9 knockout screening uncovers a novel inflammatory pathway critical for resistance to arginine-deprivation therapy |
title_sort | genome-wide crispr/cas9 knockout screening uncovers a novel inflammatory pathway critical for resistance to arginine-deprivation therapy |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7914361/ https://www.ncbi.nlm.nih.gov/pubmed/33664852 http://dx.doi.org/10.7150/thno.51795 |
work_keys_str_mv | AT chuchengying genomewidecrisprcas9knockoutscreeninguncoversanovelinflammatorypathwaycriticalforresistancetoargininedeprivationtherapy AT leeyiching genomewidecrisprcas9knockoutscreeninguncoversanovelinflammatorypathwaycriticalforresistancetoargininedeprivationtherapy AT hsiehchenghan genomewidecrisprcas9knockoutscreeninguncoversanovelinflammatorypathwaycriticalforresistancetoargininedeprivationtherapy AT yehchitai genomewidecrisprcas9knockoutscreeninguncoversanovelinflammatorypathwaycriticalforresistancetoargininedeprivationtherapy AT chaotsuyi genomewidecrisprcas9knockoutscreeninguncoversanovelinflammatorypathwaycriticalforresistancetoargininedeprivationtherapy AT chenpohung genomewidecrisprcas9knockoutscreeninguncoversanovelinflammatorypathwaycriticalforresistancetoargininedeprivationtherapy AT linihsuan genomewidecrisprcas9knockoutscreeninguncoversanovelinflammatorypathwaycriticalforresistancetoargininedeprivationtherapy AT hsiehtsunghan genomewidecrisprcas9knockoutscreeninguncoversanovelinflammatorypathwaycriticalforresistancetoargininedeprivationtherapy AT shihjingwen genomewidecrisprcas9knockoutscreeninguncoversanovelinflammatorypathwaycriticalforresistancetoargininedeprivationtherapy AT chengchiahsiung genomewidecrisprcas9knockoutscreeninguncoversanovelinflammatorypathwaycriticalforresistancetoargininedeprivationtherapy AT changchechang genomewidecrisprcas9knockoutscreeninguncoversanovelinflammatorypathwaycriticalforresistancetoargininedeprivationtherapy AT linpingsheng genomewidecrisprcas9knockoutscreeninguncoversanovelinflammatorypathwaycriticalforresistancetoargininedeprivationtherapy AT huangyuanli genomewidecrisprcas9knockoutscreeninguncoversanovelinflammatorypathwaycriticalforresistancetoargininedeprivationtherapy AT chentsungming genomewidecrisprcas9knockoutscreeninguncoversanovelinflammatorypathwaycriticalforresistancetoargininedeprivationtherapy AT yenyun genomewidecrisprcas9knockoutscreeninguncoversanovelinflammatorypathwaycriticalforresistancetoargininedeprivationtherapy AT anndavidk genomewidecrisprcas9knockoutscreeninguncoversanovelinflammatorypathwaycriticalforresistancetoargininedeprivationtherapy AT kunghsingjien genomewidecrisprcas9knockoutscreeninguncoversanovelinflammatorypathwaycriticalforresistancetoargininedeprivationtherapy |